Table 3.
Prevalence of high-risk and low-risk HPV genotypes as detected by the CLART assay in women aged 23–65 years, by cytology
| Cytology result | |||||
|---|---|---|---|---|---|
| HPV genotype | Normal (N = 4,435) | ASCUS (N = 110) | LSIL (N = 129) | ≥HSIL (N = 96) | ≥ASCUS (N = 335) |
| HPV 16 | 235 (5.3%) | 16 (14.5%) | 27 (20.9%) | 37 (38.5%) | 80 (23.9%) |
| HPV 18 | 88 (2.0%) | 7 (6.4%) | 7 (5.4%) | 15 (15.6%) | 29 (8.7%) |
| HPV 31 | 157 (3.5%) | 8 (7.3%) | 20 (15.5%) | 16 (16.7%) | 44 (13.1%) |
| HPV 33 | 98 (2.2%) | 6 (5.5%) | 13 (10.1%) | 8 (8.3%) | 27 (8.1%) |
| HPV 35 | 52 (1.2%) | 8 (7.3%) | 6 (4.7%) | 3 (3.1%) | 17 (5.1%) |
| HPV 39 | 38 (0.9%) | 5 (4.5%) | 15 (11.6%) | 2 (2.1%) | 22 (6.6%) |
| HPV 45 | 43 (1.0%) | 8 (7.3%) | 9 (7.0%) | 9 (9.4%) | 26 (7.8%) |
| HPV 51 | 139 (3.1%) | 8 (7.3%) | 10 (7.8%) | 6 (6.3%) | 24 (7.2%) |
| HPV 52 | 171 (3.9%) | 14 (12.7%) | 12 (9.3%) | 24 (25.0%) | 50 (14.9%) |
| HPV 56 | 52 (1.2%) | 6 (5.5%) | 24 (18.6%) | 1 (1.0%) | 31 (9.3%) |
| HPV 58 | 133 (3.0%) | 12 (10.9%) | 12 (9.3%) | 10 (10.4%) | 34 (10.1%) |
| HPV 59 | 90 (2.0%) | 8 (7.3%) | 13 (10.1%) | 5 (5.2%) | 26 (7.8%) |
| HPV 66 | 115 (2.6%) | 5 (4.5%) | 22 (17.1%) | 2 (2.1%) | 29 (8.7%) |
| HPV 68 | 68 (1.5%) | 4 (3.6%) | 14 (10.9%) | 8 (8.3%) | 26 (7.8%) |
| ≥1 high-risk genotype a | 923 (20.8%) | 61 (55.5%) | 93 (72.1%) | 88 (91.7%) | 242 (72.2%) |
| Single infection with a high-risk genotype a | 388 (8.7%) | 22 (20.0%) | 20 (15.5%) | 37 (38.5%) | 79 (23.6%) |
| Multiple infection including high-risk genotype(s) a | 535 (12.1%) | 39 (35.5%) | 73 (56.6%) | 51 (53.1%) | 163 (48.7%) |
| ≥1 low-risk genotype a | 943 (21.3%) | 40 (36.4%) | 88 (68.2%) | 34 (35.4%) | 162 (48.4%) |
| ≥1 low-risk genotype, no high-risk genotype a | 530 (12.0%) | 17 (15.5%) | 32 (24.8%) | 4 (4.2%) | 53 (15.8%) |
| No high- or low-risk genotype | 2,970 (67.0%) | 32 (29.1%) | 4 (3.1%) | 4 (4.2%) | 40 (11.9%) |
Abbreviations: ASCUS atypical squamous cells of undetermined significance, HC2 Hybrid Capture 2 assay, HPV Human Papillomavirus, ≥HSIL high-grade intraepithelial lesions or worse, LSIL low-grade squamous intraepithelial lesions.
aCategorization of HPV genotypes into high-risk and low-risk groups followed IARC’s classification [2], according to which genotype 66 is considered “possibly carcinogenic” (low-risk).